In the next five years, the pharmaceutical company plans to introduce a number of innovative drugs from outside

【Pharmaceutical Network Industry News】On September 1, Northeast Pharmaceutical and MedAbome signed the "MAb11-22.
1 Antibody Project Transfer, Cooperative Development and Technical Service Agreement" to introduce the MAb11-22.
1 antibody project
.

MAb11-22.
1 is a monoclonal antibody
developed by MedAbome that selectively recognizes malignant tumor cells without reacting with normal peripheral blood cells and major organ tissues.

The application of this antibody on antibody-conjugated drugs (ADC drugs) and CAR-T is currently in the preclinical development stage
.

In fact, in recent years, with the vigorous promotion of the development of the pharmaceutical innovation industry in China, R & D innovation has gradually become the key
to making pharmaceutical companies stronger and bigger.

Affected by this, more and more pharmaceutical companies have also invested in the research and development of
innovative drugs.

However, the research and development cycle of innovative drugs is long, the investment is high, and the risk is large, and it is not easy to eventually succeed, so the License in (license introduction) model has gradually become one
of the main means for domestic pharmaceutical companies to supplement their product pipelines at this stage.

Among them, in addition to the introduction of MAb11-22.
1 antibody project, Northeast Pharmaceutical plans to introduce 2 to 3 clinical stages of chemical innovative drugs and 1 to 2 clinical stages of biological innovative drugs from the outside in the next 5 years, and obtain 3 to 7 generic drug production approvals every year, steadily increasing the proportion of
new product revenue.

In addition to Northeast Pharmaceutical, in the near future, a large number of pharmaceutical companies have introduced new drugs from foreign companies and cooperated
.

For example, in August, Hansen Pharmaceutical also introduced two new drugs
.

On August 8, its wholly-owned subsidiaries, Hansen (Shanghai) Health Technology Co.
, Ltd.
and Jiangsu Haosen Pharmaceutical Group Co.
, Ltd.
, entered into an exclusive licensing agreement
with TiumBioCo.
, Ltd.
(hereinafter referred to as "TiumBio").

TU2670 is an oral active non-peptide GnRH antagonist, and early clinical trials have shown good safety and tolerability
of TU2670.

On August 22, Hansen Pharmaceutical announced that it had won the development, production and commercialization rights
of the new crown drug GDI4405 in beijing Huayi Health Drug Research Center at a down payment of 12 million yuan and a potential milestone of 1.
68 billion yuan.

Under the License Agreement, Licensee will pay a down payment of RMB12 million and potential payments of up to RMB1.
68 billion for development, registration and sales-based commercialization milestones, as well as tiered royalties
based on net sales.

In addition, in the first half of 2022, there are 7 new drugs listed that were also introduced by local pharmaceutical companies from foreign companies
.

In this regard, the industry generally believes that in the context of pharmaceutical companies actively participating in innovation competition, "License in" has become the norm
.

Pharmaceutical companies are further enriching their product lines by introducing innovative projects through the license in model to solve the dilemma
of insufficient innovation.

It should be noted that compared with the License out trading situation, which represents the innovation ability of domestic new drugs, there is still a big gap
in innovation of domestic drugs.

This shows that domestic innovative pharmaceutical companies also need to strengthen the realization of "self-hematopoiesis" in order to truly improve their competitiveness
.

In addition, from the current frequent termination of new drug research and development by many pharmaceutical companies, the termination of the clinical development of innovative drugs is inevitable, and there are certain risks in the License-in model, so how to control the risks behind the future and avoid investing funds in the water will also be a problem
that pharmaceutical companies need to think about in advance when introducing new drugs.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.